Valuation: Savara Inc

Market Cap 1.38B 1.2B 1.12B 1.03B 1.94B 132B 1.97B 13.21B 5.18B 65.8B 5.2B 5.09B 221B P/E 2026 *
-10.2x
P/E 2027 * -18.5x
Enterprise Value 1.38B 1.2B 1.12B 1.03B 1.94B 132B 1.97B 13.21B 5.18B 65.8B 5.2B 5.09B 221B EV / Sales 2026 *
543x
EV / Sales 2027 * 16.6x
Free-Float
97.41%
Yield 2026 *
-
Yield 2027 * -
06-23 Savara Insider Sold Shares Worth $2,241,432, According to a Recent SEC Filing MT
06-09 Savara Inc. Announces CFO Changes CI
06-09 Savara Inc. Announces Step Down of Dave Lowrance as Chief Administrative Officer, Effective July 15, 2026 CI
05-18 Savara Inc Announces New Exercise Capacity Data From The IMPALA-2 Phase 3 Clinical Trial Of Molgramostim Inhalation Solution In Autoimmune Pulmonary Alveolar Proteinosis CI
05-13 Savara Q1 Loss Widens MT
05-13 Earnings Flash (SVRA) Savara Posts Q1 Per Share Loss $-0.15, vs. FactSet Est of $-0.13 Loss MT
05-13 Savara Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
04-24 Oppenheimer Adjusts Price Target on Savara to $11 From $9, Maintains Outperform Rating MT
04-16 Savara announces the U.S. Food & Drug Administration (FDA) has extended the review period for the molgramostim inhalation solution (molgramostim) biologics license application (BLA) in autoimmune pulmonary alveolar proteinosis (autoimmune PAP) RE
04-16 Savara Says FDA Extended Review Period for Molgramostim Inhalation Solution Application MT
04-16 Savara Announces the U.S. Food & Drug Administration Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application in Autoimmune Pulmonary Alveolar Proteinosis CI
04-07 Savara Inc. Announces MHRA Accepts Molbreevi Marketing Authorisation Application for Autoimmune PAP CI
04-07 Savara Says UK Health Care Body Accepts Submission of Marketing Authorization Application for Molbreevi MT
Manager TitleAgeSince
Chief Executive Officer 56 01/12/2020
Director of Finance/CFO 57 15/07/2026
Chief Tech/Sci/R&D Officer 56 01/12/2023
Director TitleAgeSince
Director/Board Member 58 01/02/2009
Director/Board Member 77 01/10/2010
Director/Board Member 72 01/10/2013
Change 5-day change 1-year change 3-year change Capi.($)
+2.35%+2.74%+33.41%+79.20% 56.54B
-0.21%-7.38%+25.34%+63.02% 53.6B
-2.44%+1.40%-15.74%-16.80% 22.91B
-2.85%-7.78%-8.09%+346.36% 21.37B
+2.49%-0.92%+20.31%-12.15% 20.27B
+0.79%-1.06%+29.29%-33.32% 17.56B
+0.58%-5.88%+16.30%+540.37% 14.75B
-5.25%-4.23%+46.41%+169.05% 13.33B
+3.41%-6.61%+163.08%+280.43% 13.53B
Average -0.13%-3.79%+34.48%+157.35% 25.98B
Weighted average by Cap. +0.23%-2.96%+28.67%+119.98%

Financials

2026 *2027 *
Net sales 2.55M 2.22M 2.06M 1.9M 3.58M 244M 3.63M 24.33M 9.55M 121M 9.58M 9.37M 407M 83.42M 72.52M 67.5M 61.97M 117M 7.96B 119M 796M 312M 3.96B 313M 306M 13.29B
Net income -137M -119M -111M -102M -192M -13.08B -195M -1.31B -513M -6.51B -515M -503M -21.83B -61.66M -53.6M -49.89M -45.8M -86.5M -5.89B -87.84M -588M -231M -2.93B -232M -226M -9.83B
Net Debt - -
Logo Savara Inc
Savara Inc. is a clinical-stage biopharmaceutical company. The Company is focused on rare respiratory diseases. The Company’s lead program, molgramostim inhalation solution (MOLBREEVI or molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). MOLBREEVI is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. MOLBREEVI is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The Company is engaged in the advancement of the MOLBREEVI aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-